| 14.36 0.27 (1.92%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 18.8 | 1-year : | 21.35 |
| Resists | First : | 16.1 | Second : | 18.28 |
| Pivot price | 14.07 |
|||
| Supports | First : | 12.57 | Second : | 10.46 |
| MAs | MA(5) : | 13.6  |
MA(20) : | 14.22 |
| MA(100) : | 14.64 |
MA(250) : | 22.02 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 41 |
D(3) : | 29.3 |
| RSI | RSI(14): 49.9 |
|||
| 52-week | High : | 65.8 | Low : | 3.64 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ VOR ] has closed below upper band by 40.2%. Bollinger Bands are 36.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 14.84 - 14.9 | 14.9 - 14.97 |
| Low: | 14.04 - 14.1 | 14.1 - 14.17 |
| Close: | 14.25 - 14.34 | 14.34 - 14.46 |
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.
Sat, 13 Jun 2026
Vor Biopharma (VOR) Stock Analysis Report | Financials & Insights - Benzinga
Fri, 12 Jun 2026
Vor Biopharma (VOR) director receives 57,162 stock options for RA Capital fund - Stock Titan
Fri, 12 Jun 2026
Vor Biopharma (VOR) director receives 53,283 stock options at $14.09 strike - Stock Titan
Fri, 12 Jun 2026
Vor Biopharma (VOR) director awarded 57,162 stock options at $14.09 strike - Stock Titan
Fri, 12 Jun 2026
Vor Biopharma (VOR) grants Alexander Cumbo 56,345 stock options - Stock Titan
Fri, 12 Jun 2026
[Form 4] Vor Biopharma Inc. Insider Trading Activity - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 54 (M) |
| Shares Float | 40 (M) |
| Held by Insiders | 4.2 (%) |
| Held by Institutions | 69.3 (%) |
| Shares Short | 4,820 (K) |
| Shares Short P.Month | 4,960 (K) |
| EPS | -70.41 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.78 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -69.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -6.31 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -150 (M) |
| Levered Free Cash Flow | -189 (M) |
| PE Ratio | -0.21 |
| PEG Ratio | 0 |
| Price to Book value | -5.17 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.2 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|